title: [Organoplatinum compounds. 1987 update].
abstract: Cisplatin is one of the best available cytotoxic agents particularly in testicular, ovarian and head and neck cancer. However gastrointestinal and renal toxicities preclude greater utilisation. High dose cisplatin (200 mg/m2) has serious neurological side effects. Carboplatin gives the same therapeutic results as cisplatin in ovarian, small cell lung and head and neck cancers with a better tolerance, the main toxicity being haematological. Iproplatin seems to have no advantage over carboplatin. New derivates such as diaminocyclo-hexane-platinum seem to be promising in preclinical and phase I studies.
authors.affiliation: Clinique des Agents Anticancéreux, Hôpital Saint-Louis, Paris, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Extra
authors.forename: M
authors.initials: M
authors.lastname: Espie
authors.forename: F
authors.initials: F
authors.lastname: Calvo
authors.forename: M
authors.initials: M
authors.lastname: Marty
mesh_terms: D016190:Carboplatin; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000627:therapeutic use*
chemical_list: D009944:Organoplatinum Compounds; C023359:iproplatin; D016190:Carboplatin; D002945:Cisplatin
vernacular_title: Les organoplatines. Actualité 1987.